NYSE:GKOSMedical Equipment
Can Glaukos (GKOS) Turn Its iLution Eyelid Platform Into a Second Growth Engine Beyond Glaucoma?
Glaukos Corporation recently completed patient enrollment in its Phase 2 U.S. clinical trial of GLK-321, a physostigmine-based cream using its iLution eyelid drug-delivery platform to treat Demodex blepharitis, a chronic and often underdiagnosed eyelid disease.
This milestone not only advances Glaukos’ ocular surface pipeline but also serves as an early test of its iLution platform as a dropless alternative to traditional eye drops, potentially broadening the company’s reach beyond glaucoma...